< Back to Industry Collaborators
Funder: Novo Nordisk
Overview: The study detailed in the Novo Nordisk study protocol focused on using anonymized healthcare data to analyze treatment outcomes for patients with diabetes. It aimed to assess real-world clinical management, health outcomes, and associated costs for individuals using various therapies, including those developed by Novo Nordisk.
Why SAIL was valuable:
- SAIL offered access to anonymized, longitudinal datasets from general practice, hospital admissions, and prescribing records.
- SAIL enabled researchers to study diabetes management across a large and diverse population in Wales.
- SAIL facilitated analysis of treatment patterns and outcomes outside the controlled environment of clinical trials, providing practical insights into everyday healthcare delivery.
Results:
- The study identified key patterns in the use of diabetes treatments and their impacts on patient outcomes.
- Findings demonstrated the effectiveness of specific treatment regimens, helping to inform clinical practice and healthcare policy.
- Cost-effectiveness analyses provided insights into the financial implications of treatment options, supporting resource allocation decisions in healthcare systems.
